Skip to main content

PanoSpace

HardwareBeijing, ChinaFounded 2014· One of 1708 Hardware companies tracked by AMPulse

Develops extrusion-based and melt electrowriting bioprinting systems for tissue engineering and regenerative medicine.

CEO / Founder
Guo Min
Team Size
11-50
Stage
Active
Total Funding
$5M
Latest Round
Pre-Series A
Key Investors
CAS Star (Zhongke Chuangxing); ZGC Group (Zhongguancun Development Group)

Technology & Products

Key Products

BiOne; BioPro; BioLab; MEW

Technological Advantage

Offers a range of bioprinting systems from laboratory-scale (BioLab) to professional-grade (BioPro), integrating both standard extrusion and advanced MEW processes.

Differentiation

Value Proposition

Provides high-precision bioprinting platforms including Melt Electrowriting (MEW) for micro-scale tissue structures and regenerative medicine applications.

How They Differentiate

Focuses on the integration of Melt Electrowriting (MEW) alongside traditional extrusion bioprinting to enable micro-scale structural control in tissue engineering.

Market & Competition

Target Customers

Biomedical researchers, tissue engineers, and pharmaceutical R&D departments.

Industry Verticals

Medical; Biotechnology; Pharmaceuticals

Competitors

CELLINK; Organovo; Poietis; EnvisionTEC; Rokit

Growth & Milestones

Growth Metrics

Raised tens of millions of RMB in 2021; Systems deployed in 50+ research and medical institutions across China.

Major Milestones

2014: Company founded in Beijing; 2017: Secured Angel funding from ZGC Group; 2020: Released the BioPro and MEW series printers; 2021: Completed Pre-Series A funding round led by CAS Star

Notable Customers

Peking University Third Hospital; Tsinghua University; Beijing Institute of Technology; Chinese Academy of Sciences

https://www.3dsmartbot.com

Why this company matters

Panospace Biotech occupies an emerging niche in the bioprinting hardware market by integrating melt electrowriting (MEW) alongside conventional extrusion-based printing. While most competitors focus solely on extrusion or inkjet bioprinting, Panospace's MEW capability enables the fabrication of micro-scale fibrous scaffolds that mimic the extracellular matrix, a feature critical for tissue engineering and regenerative medicine applications.

The company's product line spans four systems: the BioLab for laboratory-scale research, the BiOne and BioPro for professional-grade work, and a dedicated MEW platform. All systems support extrusion-based bioprinting, with the MEW series adding electrohydrodynamic fiber deposition for sub-micron resolution. This dual-process approach allows researchers to combine cell-laden hydrogels with precise fiber networks in a single workflow.

Panospace's target customers are biomedical researchers, tissue engineers, and pharmaceutical R&D departments in China. Notable users include Peking University Third Hospital, Tsinghua University, Beijing Institute of Technology, and the Chinese Academy of Sciences. The company has deployed systems in over 50 research and medical institutions across China, suggesting growing adoption in academic and clinical research settings.

The company's strategic moat lies in its early specialization in MEW technology, which remains less common than extrusion bioprinting among competitors like CELLINK, Organovo, and Poietis. However, Panospace's limited geographic footprint and reliance on the Chinese research funding environment pose risks. Its partnerships with Tsinghua University and the Chinese Academy of Sciences provide technical credibility, but scaling beyond China and defending against larger global bioprinting platforms will determine long-term competitiveness.